For over 30 years, Richard Pops has been the CEO of Alkermes , a company steadfastly focused on neuroscience—a notoriously challenging therapeutic area with highly stigmatized patient populations. When Pops joined Alkermes in 1991, it was a privately held company with only 25 employees. 32 years later, the company has more than 2,000 employees and is valued at nearly $4.3B.
Unfortunately, many systemic barriers prevent patients from accessing these medications. People living with SMIs such as schizophrenia and bipolar 1 often face a challenging road to diagnosis and, even once diagnosed, may have a difficult journey finding medication that works for them.For example, due to the complex, chronic and variable nature of schizophrenia, treatment responses may differ by patient, leading some to try several medicines before finding a treatment that works for them.
The company recognizes that often individuals living with SUD and SMI require comprehensive support beyond medication—counseling, access to workforce training or re-entry services, and housing are all critical components of holistic care for these patients. According to the U.S. Substance Abuse and Mental Health Administration, 21 percent of individuals experiencing homelessness report having a serious mental illness, and 16 percent have a substance use disorder.
Caregivers play a significant role in the lives of people living with serious mental illness. And the burden on them is significant. According to a survey run by Alkermes in partnership with the Harris Poll, 72% of surveyed caregivers said their own mental health has been negatively impacted while almost 90% said that caring for their loved one takes up a lot of their mental and physical energy.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: njdotcom - 🏆 282. / 63 続きを読む »